Polypeptide Complex Limited Human
Thymalin
Bovine thymus polypeptide extract that restores T-lymphocyte function, normalises immune homeostasis, and is the most-studied natural thymic bioregulator from the Khavinson school.
In Plain English:
Thymalin is a mixture of low-molecular-weight peptides extracted from the thymus glands of young calves. It was developed in the 1970s by Vladimir Khavinson and Vyacheslav Morozov at the Military Medical Academy in St. Petersburg and has been registered as an approved immunomodulatory drug in Russia since 1982. The active fractions — dipeptides EW (glutamyl-tryptophan, marketed as Thymogen) and KE (lysyl-glutamic acid, marketed as Vilon), plus tripeptide EDP — bind directly to DNA and histone proteins, switching genes on or off to restore balanced immune responses. In clinical studies, elderly patients who received Thymalin and the pineal bioregulator Epithalamin every year for six years showed a 4.1-fold reduction in all-cause mortality compared to untreated controls. A 2021 randomised study in older COVID-19 patients found hospital mortality dropped from 40.9% to 19.4% with Thymalin added to standard care. Outside Russia it is sold as a research peptide and has no EMA, FDA, or MHRA approval.
Research Maturity
Limited Human (~293 PubMed records; 2 prospective trials (N=266) + 1 COVID-19 RCT (N=80); most from one (Khavinson) group+ Studies)
Focus
Healthy Aging
Immune Restoration
Immunity
Origin
Extracted from the thymus gland of young calves (bovine thymic cytomedin). Developed 1974-1982 by V.Kh. Khavinson and V.G. Morozov at the Military Medical Academy, St. Petersburg, USSR. Registered as a pharmaceutical drug in Russia in 1982. The key active dipeptides EW (Thymogen) and KE (Vilon) were subsequently characterised and are now synthesised independently.
Mechanism
Active dipeptides EW and KE and tripeptide EDP bind to double-stranded DNA at specific promoter regions and to histones H1/H3, modulating chromatin structure and gene transcription. Downstream effects include: induction of hematopoietic stem cell differentiation toward CD28+ T-lymphocytes (CD44 and CD117 down 2-3x; CD28 up 6.8x in vitro); restoration of CD3+, CD4+, CD8+, and NK cell counts; upregulation of IL-2 and downregulation of IL-6 and TNF-alpha; normalisation of fibrinolysis and haemostasis; enhancement of phagocytic activity; and inhibition of lymphocyte apoptosis by 29-42%.
Outcome
Mortality rate in elderly (6-8-year follow-up, n=266); T-lymphocyte subsets CD3/CD4/CD8/NK; IL-6, CRP, D-dimer (COVID-19 RCT); acute respiratory infection incidence; lymphocyte apoptosis rate; CD28 expression on hematopoietic stem cells; haemostasis markers (fibrinogen, D-dimer) in pneumonia.
